Rates of decline in Alzheimer disease decrease with age

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Holland, Dominic ^a   Desikan, Rahul S ^b   Dale, Anders M ^a,b   McEvoy, Linda K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHOPROTEIN TAU 181; TAU PROTEIN; UNCLASSIFIED DRUG;

AGE; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CEREBROSPINAL FLUID; COHORT ANALYSIS; DISEASE SEVERITY; HUMAN; LINEAR REGRESSION ANALYSIS; MILD COGNITIVE IMPAIRMENT; MORPHOMETRICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATROPHY; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84864426655     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042325     Document Type: Article

References (71)

1. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, et al. ((1995)) Age-specific incidence of Alzheimer's disease in a community population. JAMA: the journal of the American Medical Association 273:: 1354--1359.
2. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, et al. ((2002)) Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 59:: 1737--1746.
3. Brookmeyer R, Gray S, Kawas C, ((1998)) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American journal of public health 88:: 1337--1342.
4. Matthews F, Brayne C, ((2005)) The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS Med 2:: e193.
5. Brookmeyer R, Evans DA, Hebert L, Langa KM, Heeringa SG, et al. ((2011)) National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement 7:: 61--73.
6. Wan H, Sengupta M, Velkoff VA, De Barros KA (2005) 65+ in the United States: 2005. In: Bureau USC, editor. Washington, D.C.: U.S. Government Printing Office. P23-209.
7. Soto C, ((2003)) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4:: 49--60.
8. Ross CA, Poirier MA, ((2004)) Protein aggregation and neurodegenerative disease. Nat Med 10 (Suppl):: S10--17.
9. DeToma AS, Salamekh S, Ramamoorthy A, Lim MH, ((2012)) Misfolded proteins in Alzheimer's disease and type II diabetes. Chem Soc Rev 41:: 608--621.
10. Querfurth HW, LaFerla FM, ((2010)) Alzheimer's disease. N Engl J Med 362:: 329--344.
11. Braak H, Braak E, ((1991)) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:: 239--259.
12. Freeman SH, Kandel R, Cruz L, Rozkalne A, Newell K, et al. ((2008)) Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol 67:: 1205--1212.
13. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, et al. ((2009)) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30:: 1026--1036.
14. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al. ((2010)) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:: 122--131.
15. Douglas PM, Dillin A, ((2010)) Protein homeostasis and aging in neurodegeneration. J Cell Biol 190:: 719--729.
16. Brumback-Peltz C, Balasubramanian AB, Corrada MM, Kawas CH, ((2011)) Diagnosing dementia in the oldest-old. Maturitas 70:: 164--168.
17. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, et al. ((2009)) Age, neuropathology, and dementia. N Engl J Med 360:: 2302--2309.
18. Stricker NH, Chang YL, Fennema-Notestine C, Delano-Wood L, Salmon DP, et al. ((2011)) Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology 77:: 713--721.
19. Morris JC, ((1993)) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:: 2412--2414.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. ((1984)) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:: 939--944.
21. van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P, ((2011)) Early-onset versus late-onset al zheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol 10:: 280--288.
22. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM, ((2009)) Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 106:: 20954--20959.
23. Holland D, Dale AM, ((2011)) Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 15:: 489--497.
24. Holland D, McEvoy LK, Dale AM, ((2011)) Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp.
25. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, et al. ((2002)) Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33:: 341--355.
26. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, et al. ((2006)) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31:: 968--980.
27. Hua X, Gutman B, Boyle C, Rajagopalan P, Leow AD, et al. ((2011)) Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. NeuroImage 57:: 5--14.
28. Fox NC, Ridgway GR, Schott JM, ((2011)) Algorithms, atrophy and Alzheimer's disease: cautionary tales for clinical trials. Neuroimage 57:: 15--18.
29. Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, et al. ((2011)) Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 7:: 474--485 e474.
30. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, et al. ((2012)) The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 8:: S1--68.
31. Jack CR Jr, ((2012)) Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 263:: 344--361.
32. Lee GJ, Lu PH, Hua X, Lee S, Wu S, et al. ((2012)) Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions. Biol Psychiatry 71:: 814--821.
33. Reuter M, Schmansky NJ, Rosas HD, Fischl B, ((2012)) Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage.
34. Leung KK, Ridgway GR, Ourselin S, Fox NC, ((2012)) Consistent multi-time-point brain atrophy estimation from the boundary shift integral. Neuroimage 59:: 3995--4005.
35. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL, ((1982)) A new clinical scale for the staging of dementia. The British journal of psychiatry: the journal of mental science 140:: 566--572.
36. Fitzmaurice GM, Laird NM, Ware JH (2011) Applied longitudinal analysis. Hoboken, N.J.: Wiley. xxv, 701 p.
37. Rosner B (2006) Fundamentals of biostatistics. Belmont, CA: Thomson-Brooks/Cole. xix, 868 p.
38. Braak H, Braak E, ((1995)) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16:: 271--278; discussion 278-284.
39. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K, ((2006)) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:: 389--404.
40. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, et al. ((2006)) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129:: 3035--3041.
41. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, et al. ((2012)) Amyloid-beta-Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau. Arch Neurol.
42. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, et al. ((2011)) Amyloid-beta associated volume loss occurs only in the presence of phospho-tau. Ann Neurol.
43. Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, et al. ((2011)) Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimers Dement 7:: 602--610 e602.
44. Bernick C, Cummings J, Raman R, Sun X, Aisen P, ((2012)) Age and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials. Arch Neurol.
45. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, et al. ((2006)) Dissociation of neuropathology from severity of dementia in late-onset al zheimer disease. Neurology 66:: 49--55.
46. Jack CR Jr, Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, et al. ((2008)) Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 70:: 1740--1752.
47. Kennedy KM, Erickson KI, Rodrigue KM, Voss MW, Colcombe SJ, et al. ((2009)) Age-related differences in regional brain volumes: a comparison of optimized voxel-based morphometry to manual volumetry. Neurobiol Aging 30:: 1657--1676.
48. Walhovd KB, Westlye LT, Amlien I, Espeseth T, Reinvang I, et al. ((2011)) Consistent neuroanatomical age-related volume differences across multiple samples. Neurobiol Aging 32:: 916--932.
49. Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, et al. ((2012)) Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging 33:: 845--855.
50. Hastie T, Tibshirani R (1990) Generalized additive models. London; New York: Chapman and Hall. xv, 335 p.
51. Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, et al. ((2005)) Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 15:: 1676--1689.
52. Raz N, Ghisletta P, Rodrigue KM, Kennedy KM, Lindenberger U, ((2010)) Trajectories of brain aging in middle-aged and older adults: regional and individual differences. Neuroimage 51:: 501--511.
53. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, et al. ((2002)) Incidence of AD may decline in the early 90 s for men, later for women: The Cache County study. Neurology 58:: 209--218.
54. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC, ((2004)) Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 61:: 518--524.
55. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, et al. ((1999)) APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 53:: 321--331.
56. Jellinger KA, Attems J, ((2010)) Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 119:: 421--433.
57. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH, ((2010)) Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 67:: 114--121.
58. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. ((2011)) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:: 263--269.
59. Sperling RA, Jack CR Jr, Aisen PS, ((2011)) Testing the right target and right drug at the right stage. Sci Transl Med 3:: 111cm133.
60. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM, ((2007)) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3:: 186--191.
61. Alzheimer's Association, ((2010)) 2010 Alzheimer's disease facts and figures. Alzheimers Dement 6:: 158--194.
62. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. ((2010)) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9:: 119--128.
63. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM, ((2010)) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6:: 67--77.
64. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, et al. ((2010)) Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6:: 230--238.
65. Caroli A, Frisoni GB, ((2010)) The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 31:: 1263--1274.
66. Lomasko T, Lumsden CJ, ((2009)) One-hit stochastic decline in a mechanochemical model of cytoskeleton-induced neuron death III: diffusion pulse death zones. J Theor Biol 256:: 104--116.
67. Clarke G, Lumsden CJ, McInnes RR, ((2001)) Inherited neurodegenerative diseases: the one-hit model of neurodegeneration. Human molecular genetics 10:: 2269--2275.
68. Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, et al. ((2012)) Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Arch Neurol.
69. Sinka L, Kovari E, Gold G, Hof PR, Herrmann FR, et al. ((2010)) Small vascular and Alzheimer disease-related pathologic determinants of dementia in the oldest-old. J Neuropathol Exp Neurol 69:: 1247--1255.
70. Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, et al. ((2007)) Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia. Neurology 68:: 927--931.
71. Gold G, Giannakopoulos P, Herrmann FR, Bouras C, Kovari E, ((2007)) Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 130:: 2830--2836.